Patient Derived Xenograft (PDX) Models Market Trends [2030]
Patient Derived Xenograft (PDX) Models Market Trends [2030]
Segments - Global Patient Derived Xenograft (PDX) Models Market By Type (Mice Models and Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models, and Others), Application (Preclinical Drug Development, Biomarker Analysis, Basic Cancer Research), End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Academic & Research Institutions), and Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2020 – 2027
Upcoming
| Report ID :HC-2512
| 4.1 Rating
| 85 Reviews
| 296 Pages
| Format :
Report Description
Patient Derived Xenograft (PDX) Models Market Outlook
The Global Patient Derived Xenograft (PDX) Models Market was valued at USD 113.5 Million in 2019 and is anticipated to reach 283.3 Million by 2027, expanding at a CAGR of 14.5% during the forecast period. Patient-derived xenografts (PDX) are models of cancer in which the cells from a patient’s tumor are inserted into an immune deficient or humanized mouse.
PDX models simulate that human tumor biology is allowing for natural cancer progression and offers translational research for calculating the desired result. Patient-derived xenograft (PDX) mouse models includes the insertion of fresh human tumor samples directly into the immune-deficient mice by surgery. Xenograft animal models are required for testing the effectiveness of medicines and are mostly required in drug advancement for cancer, diabetes, infections, etc.
Gene expression in tumors is maintained by sequential path of tumors from mouse to mouse. These models support research for tumor biology and pharmacology deprived of manual influence of cell cultures and are usually used in modified cancer therapy, drug enlargement and clinical tests. PDX models show advanced predictive values for clinical results than cell line‑derived xenograft models and hereditarily engineered mouse models.
Patient Derived Xenograft (PDX) Models Market Dynamics
The market is driven by factors such as Rising governments support for pharmaceutical and biotechnology industries, growing demand for personalized medicines, increasing R&D activities by pharmaceutical and biotechnology companies, surging number of preclinical studies for developing anti-cancer drugs for solid tumors.
Conversely, high cost of personalized PDX models, implementation of stringent guidelines on the use of animal models in cancer research. Rising demand for humanized PDX models is one the major factors anticipated to create lucrative opportunities in the market.
Patient Derived Xenograft (PDX) Models Market Segmental Outlook
Based on types, the Global Patient Derived Xenograft (PDX) Models Market is fragmented into mice models and rat models. Mice models segment is anticipated to hold the largest market share during the forecast period. Ease of procurement, manipulation, and the minimum facilities required for keeping mice models under observation in comparison to rats is driving the PDX models market.
Rising development of biotechnological goods and new medical devices is expected to boost the global patient-derived xenograft (PDX) market. New competitive market players bringing innovative healthcare solutions is anticipated to grow the preclinical testing market, which is expected to increase the demand for rat models. Introduction of immunodeficient rats drives the use of rat models in the PDX models market. Rat models segment is anticipated to boost at a substantial growth rate during the forecast period. Factors which drives this market consists of the larger size of rats, which enhances surgical manipulation.
On the basis of tumor types, the global patient-derived xenografts (PDX) models market is segmented into gynecological tumor models, gastrointestinal tumor models, urological tumor models, respiratory tumor models, hematological tumor models, and other tumor models. The gastrointestinal tumor models segment is anticipated to dominate the global patient-derived xenografts (PDX) models market, due to rising number of gastrointestinal tumor models and growing gastrointestinal tumor research in academic & research institutions and contract research organizations (CROs).
The respiratory tumor model segment is expected to grow at the highest rate during the forecast period. Factors attributing to the growth of the segment includes increasing research activities in the oncology field and growing focus of competitive market players on generating lung cancer PDX models, due to increasing number of cancer cases. Funds for companies involved in cancer research are anticipated to grow at a rapid pace during forecast period for the global patient-derived xenografts (PDX) models market.
Based on applications, the global patient-derived xenografts (PDX) models market is fragmented into preclinical drug development, biomarker analysis, and basic cancer research. Preclinical drug development segment is anticipated to reach the maximum growth rate in the PDX models market during the forecast period. Compound annual growth rate of this segment is attributed to increasing number of clinical tests.
The basic cancer research and preclinical drug development segment accounts for a large market share of the global PDX models market. The segment is important, due to rising number of research activities in the oncology drug research field. The basic cancer research disease segment is anticipated to grow at a substantial rate, due to increasing adoption of PDX models for basic cancer research. Basic cancer research is the characterization of cancer biology and exploring mechanisms that are involved for prediction or having a knowledge of cancer.
Based on end-users, the global patient-derived xenograft (PDX) models is fragmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Academic & Research Institutions. The academic & research organizations segment dominates the market, as the usage of PDX models is growing for basic cancer research and characterization of cancer biology, tumorigenesis, and metastasis.
The contract research organizations segment is anticipated to grow at a high CAGR during the forecast period. Market growth rate in this segment are attributed to rising number of pharmaceutical companies, which outsource preclinical studies to CROs. The pharmaceutical and biotechnology companies segment is growing at a rapid pace, owing to the boost provided by the ongoing pandemic.
Market players are focusing on developing new and efficient products to cater to the growing needs of the market. The segment is predicted to grow at a substantial rate.
Regional Outlook
Based on regions, the global Patient Derived Xenograft (PDX) Models market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a major share of the market, followed by Europe. The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing preclinical activities by CROs and pharmaceutical companies and rapid growth in onco-immunology research are some of the factors driving the market in North America.
Moreover, the market in Asia Pacific is expected to grow due to rising prevalence of cancer and increasing government expenditure on pharmaceutical R&D. It is also estimated to grow at the highest CAGR in the PDX models market during the forecast period, mainly owing to factors such as increasing trend of outsourcing drug discovery services, and growing life sciences research.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Patient Derived Xenograft (PDX) Models Market
- Historical, Current and Projected Market Size in terms of Value and Volume
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Patient Derived Xenograft (PDX) Models Market Performance
Segments
By Type
- Mice Models
- Rat Models
By Tumor Type
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Hematological Tumor Models
- Others
By Application
- Preclinical Drug Development
- Biomarker Analysis
- Basic Cancer Research
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Players
- Abnova Corporation
- Aragen Bioscience, a GVKBIO Company
- Bioduro
- Champions Oncology, Inc.
- Charles River Laboratories
- Envigo
- EPO Berlin-Buch GmbH
- Explora BioLabs
- Hera Biolabs
- NexusPharma
- Oncodesign
- THE JACKSON LABORATORY
- Urosphere
- WuXi AppTec
- Xentech
Competitive Landscape
- Top players in the market include THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, and Charles River Laboratories. These companies are considered as key manufacturers of Patient Derived Xenograft (PDX) Models based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
- The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Patient Derived Xenograft (PDX) Models market.
- On March 02, 2021, Explora BioLabs launched two facilities in San Diego, in the US. The launch of these facilities is expected to expand Explora BioLabs’s footprints in San Diego from seven to nine on-demand vivaria.
- On February 25, 2021, Charles River Laboratories, entered into a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Through this partnership, together with leading expertise in early-stage preclinical testing, researchers can utilize the Kibur technology to perform in vivo testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models.
- In January 2021, Endo International plc launched Authorized Generic Version of Amitiza (lubiprostone) Capsules in the US.
Frequently Asked Questions
Major manufactures include, THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, Charles River Laboratories, Explora BioLabs, Champions Oncology, Inc. and others.
Factors such as Surgical Treatment, Healthcare Expenditure, Technological Advancements, Export & Import Scenario, Price of Drugs, and GDP are analyzed in the final report.
The base year considered for the Global Patient Derived Xenograft (PDX) Models market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017, and 2018 are the historic years, and the forecast is provided from 2020 to 2027.
The market is expected to show decline of -3.2% in growth market between 2019 and 2020 owing to the COVID 19 pandemic effect on the Patient Derived Xenograft (PDX) Models market.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Usage of PDX model in preclinical drug development, biomarker analysis, and basic cancer research studies are the major applications of the Patient Derived Xenograft (PDX) Models.
Rising governments support for pharmaceutical and biotechnology industries, growing demand for personalized medicines, increasing R&D activities by pharmaceutical and biotechnology companies, and surging number of preclinical studies for developing anti-cancer drugs for solid tumors are the factors expected to drive the market growth during forecast period.
In addition to market size (in US$ Million), Company Market Share (in % for base year 2019), Regulatory Landscape, Technology Landscape, Patent Analysis, Consumer Survey, and Pipeline/Clinical Trial Analysis.
According to this Growth Market Reports, the Patient Derived Xenograft (PDX) Models market is likely to register a CAGR of 14.5% during forecast period 2020-2027, with an anticipated valuation of USD 283.3 million by the end of the 2027.
Additional company profiles can be provided on request
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Patient Derived Xenograft (PDX) Models Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Patient Derived Xenograft (PDX) Models Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Patient Derived Xenograft (PDX) Models Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Patient Derived Xenograft (PDX) Models Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Patient Derived Xenograft (PDX) Models Market Size & Forecast, 2017-2027
4.5.1 Patient Derived Xenograft (PDX) Models Market Size and Y-o-Y Growth
4.5.2 Patient Derived Xenograft (PDX) Models Market Absolute $ Opportunity
4.6 Regulatory Landscape
4.7 Technology Landscape
4.8 Patent Analysis
4.9 Consumer Survey
4.10 Pipeline /Clinical Trial Analysis
Chapter 5 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
5.2.1 Mice Models
5.2.2 Rat Models
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By Tumor Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Tumor Type
6.1.2 Basis Point Share (BPS) Analysis By Tumor Type
6.1.3 Absolute $ Opportunity Assessment By Tumor Type
6.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
6.2.1 Gastrointestinal Tumor Models
6.2.2 Gynecological Tumor Models
6.2.3 Respiratory Tumor Models
6.2.4 Urological Tumor Models
6.2.5 Hematological Tumor Models
6.2.6 Others
6.3 Market Attractiveness Analysis By Tumor Type
Chapter 7 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Application
7.1.2 Basis Point Share (BPS) Analysis By Application
7.1.3 Absolute $ Opportunity Assessment By Application
7.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
7.2.1 Preclinical Drug Development
7.2.2 Biomarker Analysis
7.2.3 Basic Cancer Research
7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By End-user
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-user
8.1.2 Basis Point Share (BPS) Analysis By End-user
8.1.3 Absolute $ Opportunity Assessment By End-user
8.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
8.2.1 Pharmaceutical & Biotechnology Companies
8.2.2 Contract Research Organizations (CROs)
8.2.3 Academic & Research Institutions
8.3 Market Attractiveness Analysis By End-user
Chapter 9 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 Patient Derived Xenograft (PDX) Models Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Patient Derived Xenograft (PDX) Models Analysis and Forecast
11.1 Introduction
11.2 North America Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
11.6.1 Mice Models
11.6.2 Rat Models
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
11.10.1 Gastrointestinal Tumor Models
11.10.2 Gynecological Tumor Models
11.10.3 Respiratory Tumor Models
11.10.4 Urological Tumor Models
11.10.5 Hematological Tumor Models
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis By Tumor Type
11.12 Absolute $ Opportunity Assessment By Tumor Type
11.13 Market Attractiveness Analysis By Tumor Type
11.14 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
11.14.1 Preclinical Drug Development
11.14.2 Biomarker Analysis
11.14.3 Basic Cancer Research
11.15 Basis Point Share (BPS) Analysis By Application
11.16 Absolute $ Opportunity Assessment By Application
11.17 Market Attractiveness Analysis By Application
11.18 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
11.18.1 Pharmaceutical & Biotechnology Companies
11.18.2 Contract Research Organizations (CROs)
11.18.3 Academic & Research Institutions
11.19 Basis Point Share (BPS) Analysis By End-user
11.20 Absolute $ Opportunity Assessment By End-user
11.21 Market Attractiveness Analysis By End-user
Chapter 12 Europe Patient Derived Xenograft (PDX) Models Analysis and Forecast
12.1 Introduction
12.2 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
12.6.1 Mice Models
12.6.2 Rat Models
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
12.10.1 Gastrointestinal Tumor Models
12.10.2 Gynecological Tumor Models
12.10.3 Respiratory Tumor Models
12.10.4 Urological Tumor Models
12.10.5 Hematological Tumor Models
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis By Tumor Type
12.12 Absolute $ Opportunity Assessment By Tumor Type
12.13 Market Attractiveness Analysis By Tumor Type
12.14 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
12.14.1 Preclinical Drug Development
12.14.2 Biomarker Analysis
12.14.3 Basic Cancer Research
12.15 Basis Point Share (BPS) Analysis By Application
12.16 Absolute $ Opportunity Assessment By Application
12.17 Market Attractiveness Analysis By Application
12.18 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
12.18.1 Pharmaceutical & Biotechnology Companies
12.18.2 Contract Research Organizations (CROs)
12.18.3 Academic & Research Institutions
12.19 Basis Point Share (BPS) Analysis By End-user
12.20 Absolute $ Opportunity Assessment By End-user
12.21 Market Attractiveness Analysis By End-user
Chapter 13 Asia Pacific Patient Derived Xenograft (PDX) Models Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
13.6.1 Mice Models
13.6.2 Rat Models
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
13.10.1 Gastrointestinal Tumor Models
13.10.2 Gynecological Tumor Models
13.10.3 Respiratory Tumor Models
13.10.4 Urological Tumor Models
13.10.5 Hematological Tumor Models
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis By Tumor Type
13.12 Absolute $ Opportunity Assessment By Tumor Type
13.13 Market Attractiveness Analysis By Tumor Type
13.14 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
13.14.1 Preclinical Drug Development
13.14.2 Biomarker Analysis
13.14.3 Basic Cancer Research
13.15 Basis Point Share (BPS) Analysis By Application
13.16 Absolute $ Opportunity Assessment By Application
13.17 Market Attractiveness Analysis By Application
13.18 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
13.18.1 Pharmaceutical & Biotechnology Companies
13.18.2 Contract Research Organizations (CROs)
13.18.3 Academic & Research Institutions
13.19 Basis Point Share (BPS) Analysis By End-user
13.20 Absolute $ Opportunity Assessment By End-user
13.21 Market Attractiveness Analysis By End-user
Chapter 14 Latin America Patient Derived Xenograft (PDX) Models Analysis and Forecast
14.1 Introduction
14.2 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
14.6.1 Mice Models
14.6.2 Rat Models
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
14.10.1 Gastrointestinal Tumor Models
14.10.2 Gynecological Tumor Models
14.10.3 Respiratory Tumor Models
14.10.4 Urological Tumor Models
14.10.5 Hematological Tumor Models
14.10.6 Others
14.11 Basis Point Share (BPS) Analysis By Tumor Type
14.12 Absolute $ Opportunity Assessment By Tumor Type
14.13 Market Attractiveness Analysis By Tumor Type
14.14 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
14.14.1 Preclinical Drug Development
14.14.2 Biomarker Analysis
14.14.3 Basic Cancer Research
14.15 Basis Point Share (BPS) Analysis By Application
14.16 Absolute $ Opportunity Assessment By Application
14.17 Market Attractiveness Analysis By Application
14.18 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
14.18.1 Pharmaceutical & Biotechnology Companies
14.18.2 Contract Research Organizations (CROs)
14.18.3 Academic & Research Institutions
14.19 Basis Point Share (BPS) Analysis By End-user
14.20 Absolute $ Opportunity Assessment By End-user
14.21 Market Attractiveness Analysis By End-user
Chapter 15 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
15.6.1 Mice Models
15.6.2 Rat Models
15.7 Basis Point Share (BPS) Analysis By Type
15.8 Absolute $ Opportunity Assessment By Type
15.9 Market Attractiveness Analysis By Type
15.10 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
15.10.1 Gastrointestinal Tumor Models
15.10.2 Gynecological Tumor Models
15.10.3 Respiratory Tumor Models
15.10.4 Urological Tumor Models
15.10.5 Hematological Tumor Models
15.10.6 Others
15.11 Basis Point Share (BPS) Analysis By Tumor Type
15.12 Absolute $ Opportunity Assessment By Tumor Type
15.13 Market Attractiveness Analysis By Tumor Type
15.14 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
15.14.1 Preclinical Drug Development
15.14.2 Biomarker Analysis
15.14.3 Basic Cancer Research
15.15 Basis Point Share (BPS) Analysis By Application
15.16 Absolute $ Opportunity Assessment By Application
15.17 Market Attractiveness Analysis By Application
15.18 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
15.18.1 Pharmaceutical & Biotechnology Companies
15.18.2 Contract Research Organizations (CROs)
15.18.3 Academic & Research Institutions
15.19 Basis Point Share (BPS) Analysis By End-user
15.20 Absolute $ Opportunity Assessment By End-user
15.21 Market Attractiveness Analysis By End-user
Chapter 16 Competition Landscape
16.1 Patient Derived Xenograft (PDX) Models Market: Competitive Dashboard
16.2 Global Patient Derived Xenograft (PDX) Models Market: Market Share Analysis, 2019
16.3 Company Profiles (Details - Overview, Financials, Developments, Strategy)
16.3.1 Abnova Corporation
16.3.2 Aragen Bioscience, a GVKBIO Company
16.3.3 Bioduro
16.3.4 Champions Oncology, Inc.
16.3.5 Charles River Laboratories
16.3.6 Envigo
16.3.7 EPO Berlin-Buch GmbH
16.3.8 Explora BioLabs
16.3.9 Hera Biolabs
16.3.10 NexusPharma
16.3.11 Oncodesign
16.3.12 THE JACKSON LABORATORY
16.3.13 Urosphere
16.3.14 WuXi AppTec
16.3.15 Xentech
Methodology
Related Reports
Some other reports from this category!
Our Clients
